About Ironwood Pharmaceuticals, Inc.
https://www.ironwoodpharma.comIronwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.
CEO
Thomas A. McCourt
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-04-02 | Forward | 597:500 |
ETFs Holding This Stock
Summary
Showing Top 3 of 106
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Craig-Hallum
Buy
JMP Securities
Market Outperform
Wells Fargo
Equal Weight
Leerink Partners
Market Perform
Jefferies
Hold
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:22.88M
Value:$103.86M
ARMISTICE CAPITAL, LLC
Shares:16.15M
Value:$73.32M
VANGUARD GROUP INC
Shares:16.07M
Value:$72.97M
Summary
Showing Top 3 of 234
About Ironwood Pharmaceuticals, Inc.
https://www.ironwoodpharma.comIronwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $122.06M ▲ | $46.58M ▲ | $40.08M ▲ | 32.84% ▲ | $0.25 ▲ | $76.93M ▲ |
| Q2-2025 | $85.24M ▲ | $39.92M ▼ | $23.6M ▲ | 27.69% ▲ | $0.15 ▲ | $46.65M ▲ |
| Q1-2025 | $41.14M ▼ | $42.82M ▼ | $-37.39M ▼ | -90.87% ▼ | $-0.23 ▼ | $-10.07M ▼ |
| Q4-2024 | $90.55M ▼ | $59.05M ▲ | $2.26M ▼ | 2.49% ▼ | $0.01 ▼ | $33.39M ▲ |
| Q3-2024 | $91.59M | $36.13M | $3.65M | 3.98% | $0.02 | $27.3M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $140.41M ▲ | $396.06M ▲ | $660.22M ▲ | $-264.16M ▲ |
| Q2-2025 | $92.85M ▼ | $342.95M ▲ | $651.11M ▼ | $-308.16M ▲ |
| Q1-2025 | $108.48M ▲ | $327.21M ▼ | $661.27M ▲ | $-334.05M ▼ |
| Q4-2024 | $88.56M ▲ | $350.91M ▼ | $652.24M ▼ | $-301.33M ▲ |
| Q3-2024 | $88.21M | $389.52M | $700.85M | $-311.33M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $40.08M ▲ | $47.58M ▲ | $-2K | $0 ▼ | $47.55M ▲ | $47.58M ▲ |
| Q2-2025 | $23.6M ▲ | $-15.07M ▼ | $-2K ▲ | $88K ▲ | $-15.63M ▼ | $-15.07M ▼ |
| Q1-2025 | $-37.39M ▼ | $19.95M ▲ | $-31K ▼ | $6K ▲ | $19.92M ▲ | $19.92M ▲ |
| Q4-2024 | $3.19M ▼ | $15.21M ▲ | $0 ▲ | $-14.89M ▲ | $348K ▲ | $15.21M ▲ |
| Q3-2024 | $3.65M | $9.88M | $-16K | $-27.16M | $-17.31M | $9.87M |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 Collaborative arrangement collaboration and license agreements | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Collaborative arrangement other agreements | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Collaborative arrangements revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Royalty | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|---|
 Europe And Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 North America | $180.00M ▲ | $90.00M ▼ | $120.00M ▲ | $40.00M ▼ |
CEO
Thomas A. McCourt
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-04-02 | Forward | 597:500 |
ETFs Holding This Stock
Summary
Showing Top 3 of 106
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Craig-Hallum
Buy
JMP Securities
Market Outperform
Wells Fargo
Equal Weight
Leerink Partners
Market Perform
Jefferies
Hold
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:22.88M
Value:$103.86M
ARMISTICE CAPITAL, LLC
Shares:16.15M
Value:$73.32M
VANGUARD GROUP INC
Shares:16.07M
Value:$72.97M
Summary
Showing Top 3 of 234